ERBB2 and breast cancer: A pooled analysis by the FDA showed that all clinicopathological subgroups of patients with HR-positive, HER2-negative advanced breast cancer benefited from CDK4/6 inhibitors when combined with CDK4/6 inhibitors as first-line therapy, regardless of PR expression.